title: [Preclinical studies of an adsorbed diphtheria-tetanus-pertussis vaccine (ADTP-vaccine) with acellular pertussis component].
abstract: OBJECTIVE
  Evaluate standardness of antigenic composition of pertussis component, completeness of sorption of pertussis, diphtheria and tetanus components, specific activity and safety of experimental series ofADTP-vaccine with acellular pertussis component (ADTaP-vaccine).
  
  
  METHODS
  The content of separate antigens (pertussis toxin, filamentous hemagglutinin and agglutinogens 1, 2, 3) in samples of acellular pertussis component of ADTaP-vaccine and completeness of sorption of pertussis component of ADTaP-vaccine were evaluated by using enzyme immunoassay. Completeness of sorption of diphtheria and tetanus components were determined in flocculation reaction and antitoxin-binding reactions, respectively. Protective activity ofADTaP-vaccine was studied in model ofmeningoencephalitis development in mice infected with Bordetella pertussis (strain 18323) neurotropic virulent culture, protective activity oftetanus component - by survival of mice after administration of tetanus toxin, protective activity of diphtheria component - by survival of guinea pigs after administration of diphtheria toxin. Safety of preparations was evaluated in tests of acute and chronic toxicity with carrying out pathomorphologic studies including immature animals.
  
  
  RESULTS
  All the studied experimental series ofADTaP-vaccine were standard by content of separate antigens of pertussis microbe. All the ADTaP-vaccine components were completely sorbed on aluminium hydroxide gel. By protective activity ADTaP preparations satisfied the WHO requirements. The preparations were non-toxic in acute and chronic toxicity and did not induce pathomorphologic changes including immature animals.
  
  
  CONCLUSIONS
  Experimental samples of ADTaP-vaccine by specific activity and safety satisfied WHO requirements.
authors.forename: E M
authors.initials: EM
authors.lastname: Zaĭtsev
authors.forename: M V
authors.initials: MV
authors.lastname: Britsina
authors.forename: I G
authors.initials: IG
authors.lastname: Bazhanova
authors.forename: N U
authors.initials: NU
authors.lastname: Mertsalova
authors.forename: M N
authors.initials: MN
authors.lastname: Ozeretskovskaia
authors.forename: E V
authors.initials: EV
authors.lastname: Ermolova
authors.forename: N G
authors.initials: NG
authors.lastname: Plekhanova
authors.forename: N A
authors.initials: NA
authors.lastname: Mikhaĭlova
authors.forename: V A
authors.initials: VA
authors.lastname: Kolyshkin
authors.forename: V V
authors.initials: VV
authors.lastname: Zverev
mesh_terms: D000276:Adjuvants, Immunologic / Q000009:adverse effects* / Q000494:pharmacology; D000536:Aluminum Hydroxide / Q000009:adverse effects / Q000494:pharmacology*; D000818:Animals; D000942:Antigens, Bacterial / Q000009:adverse effects / Q000276:immunology / Q000494:pharmacology*; D001886:Bordetella pertussis; D004167:Diphtheria Toxin / Q000276:immunology / Q000633:toxicity*; D022681:Diphtheria-Tetanus-acellular Pertussis Vaccines / Q000009:adverse effects / Q000276:immunology / Q000494:pharmacology*; D004353:Drug Evaluation, Preclinical; D005260:Female; D006168:Guinea Pigs; D006801:Humans; D008297:Male; D008590:Meningoencephalitis / Q000276:immunology / Q000517:prevention & control*; D051379:Mice; D013744:Tetanus Toxin / Q000276:immunology / Q000633:toxicity*
chemical_list: D000276:Adjuvants, Immunologic; D000942:Antigens, Bacterial; D004167:Diphtheria Toxin; D022681:Diphtheria-Tetanus-acellular Pertussis Vaccines; D013744:Tetanus Toxin; D000536:Aluminum Hydroxide